Optimization of a novel series of potent and orally bioavailable GPR119 agonists

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3249-3253. doi: 10.1016/j.bmcl.2017.06.034. Epub 2017 Jun 13.

Abstract

We describe the discovery and optimization of a novel series of furo[3,2-d]pyrimidines as G protein-coupled receptor 119 agonists. Agonistic activity of 4 (EC50=129nM) was improved by replacing the intramolecular hydrogen bond between the fluorine atom and the aniline hydrogen in the head moiety with a covalent C-C bond to enhance conformational restriction, which consequently gave a lead compound 12 (EC50=53nM). Optimized compound 26, which was identified by the further optimization of 12, exhibited potent activity (EC50=42nM) with improved clearance in liver microsomes and induced a 33% reduction in blood glucose area under the curve at a dose of 10mg/kg in an oral glucose tolerance test in C57BL/6N mice.

Keywords: Furo[3,2-d]pyrimidine; GPR119 agonists; Intramolecular hydrogen bond; Restricted conformation; Type 2 diabetes mellitus.

MeSH terms

  • Administration, Oral
  • Animals
  • Blood Glucose / analysis
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Glucose Tolerance Test
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / chemistry*
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / pharmacology*
  • Mice, Inbred C57BL
  • Pyrimidines / administration & dosage
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology*
  • Receptors, G-Protein-Coupled / agonists*
  • Receptors, G-Protein-Coupled / metabolism
  • Structure-Activity Relationship

Substances

  • Blood Glucose
  • GPR119 protein, human
  • Hypoglycemic Agents
  • Pyrimidines
  • Receptors, G-Protein-Coupled